Curing cancer or curbing immigration: A question of national morality and priority

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul W. Thurman, DBA
Professor of management and analytics, Joseph L. Mailman School of Public Health, Columbia University Medical Center, Columbia University
Table of Contents

YOU MAY BE INTERESTED IN

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 
Paul W. Thurman, DBA
Professor of management and analytics, Joseph L. Mailman School of Public Health, Columbia University Medical Center, Columbia University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login